Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLK), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
Outlook Therapeutics, Inc. develops and commercializes ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retina diseases, including wet age-related macular degeneration. Company news commonly covers the product’s European Commission and MHRA marketing authorizations, commercial launch activity in Germany, Austria and the UK, and U.S. regulatory communications involving the biologics license application pathway for neovascular AMD.
Updates also include capital-structure actions used to fund operations, such as public offerings, registered direct offerings, warrants, convertible-note amendments and note financing. Governance and shareholder-approval matters appear in connection with securities issuance and authorized-share requirements.
Outlook Therapeutics (Nasdaq: OTLK) reported Q2 FY2026 results and corporate updates. Net loss attributable to common stockholders was $4.5 million, or $0.05 per share, versus $46.4 million, or $1.50, a year earlier. Adjusted net loss was $14.1 million versus $12.4 million.
The company advanced LYTENAVA™ commercialization in Europe, signed a Swiss distribution deal with Mediconsult AG targeting a 2027 launch, and started a real-world evidence study in Germany. An FDA formal dispute resolution decision on ONS-5010/LYTENAVA™ is expected in May 2026. Cash was $7.7 million as of March 31, 2026.
Outlook Therapeutics (Nasdaq: OTLK) closed a registered direct offering of 16,129,033 common shares at $0.31 per share, generating approximately $5.0 million gross proceeds. The company concurrently issued unregistered warrants for up to 16,129,033 shares at a $0.31 exercise price, potentially raising an additional $5.0 million if exercised. The company amended existing warrants (2,142,854 shares) to a $0.31 exercise price; warrants’ exercisability and resale depend on stockholder approval and charter amendment timing. Net proceeds will be used primarily for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) announced a registered direct offering of 16,129,033 shares (or pre-funded warrants) at $0.31 per share and concurrent private-placement unregistered warrants to purchase up to 16,129,033 shares.
The offering is expected to close on or about April 23, 2026, raising approximately $5.0 million gross, with potential additional gross proceeds of about $5.0 million if the unregistered warrants are fully exercised. Proceeds are intended for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) completed a Federal Dispute Resolution meeting with the FDA concerning its ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application for neovascular age-related macular degeneration. A formal FDA response is expected in May 2026. The company said it will update investors after receiving the official feedback.
Outlook Therapeutics (Nasdaq: OTLK) announced that the FDA accepted its Formal Dispute Resolution Request (FDRR) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) and granted a meeting with the deciding official in April 2026. The FDRR follows a December 30, 2025 Complete Response Letter and a March 2, 2026 Type A meeting.
Outlook cites Phase 3 NORSE TWO and NORSE EIGHT data that it says support efficacy and safety; the company reports no FDA safety concerns and notes a U.S. end-to-end manufacturing supply chain.
Outlook Therapeutics (Nasdaq: OTLK) closed a public offering on March 25, 2026, selling 20,000,000 shares of common stock together with warrants to purchase up to 20,000,000 shares at a combined public offering price of $0.25 per share and warrant.
The offering generated aggregate gross proceeds of $5.0 million before fees; the warrants have a $0.25 exercise price, are exercisable immediately and expire five years from issuance. The company intends to use net proceeds primarily for working capital and general corporate purposes.
Outlook Therapeutics (Nasdaq: OTLK) priced a public offering of 20,000,000 shares and accompanying warrants to buy 20,000,000 shares at a combined price of $0.25 per share/warrant, yielding aggregate gross proceeds of $5.0 million before fees.
Each warrant is exercisable immediately at $0.25 and expires five years from issuance; the offering is expected to close on or about March 25, 2026.
Outlook Therapeutics (Nasdaq: OTLK) announced on March 23, 2026 that it has commenced a best-efforts public offering of common stock (or pre-funded warrants) and accompanying warrants exercisable for common stock. The offering is subject to market and other conditions and may not be completed.
H.C. Wainwright is the exclusive placement agent. Net proceeds are intended primarily for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (File No. 333-278340); a prospectus supplement will be filed with the SEC.
Outlook Therapeutics (Nasdaq: OTLK) announced an amendment and a new financing on March 16, 2026. The company extended the Avondale convertible note maturity to Dec 31, 2026 and issued an $18.4 million non-convertible unsecured note to Atlas Sciences.
Outlook expects $17.0 million net proceeds after original issue discount, will use proceeds to pay down the Existing Note leaving ~$10.8 million of principal and interest, and the New Note matures on June 16, 2027 with interest = Prime + 3% (minimum 9.5% per annum).
Outlook Therapeutics (Nasdaq: OTLK) provided a regulatory update after a Type A meeting with the U.S. FDA regarding the Dec 30, 2025 Complete Response Letter for its BLA for ONS-5010/LYTENAVA (bevacizumab-vikg). The meeting focused on the FDA’s outstanding substantial-evidence issue and potential paths to approval.
NORSE TWO met its primary and key secondary endpoints with clinically meaningful, statistically significant visual-acuity improvements; NORSE EIGHT and other data were submitted as confirmatory evidence. The FDA identified no safety concerns. The company is evaluating regulatory options and continuing discussions to clarify confirmatory evidence and next steps toward potential U.S. approval.